Compare Oruka Therapeutics Inc. Common Stock (ORKA) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oruka Therapeutics Inc. Common Stock vs J M Smucker Co — how do they compare? Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B), while J M Smucker Co trades at $122 (market cap $12.96B). The key difference: J M Smucker Co is far larger — about 2.5× Oruka Therapeutics Inc. Common Stock's market cap, and J M Smucker Co pays a 3.69% dividend while Oruka Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oruka Therapeutics Inc. Common Stock for 0 Days and J M Smucker Co for 74 Days on average.
| ORKA | SJM | |
|---|---|---|
Market Cap | $5.18B | $12.96B |
Volume | 490,798 | 1,039,289 |
Sector | Health | Consumer Staples |
52-Week High | $113.08 | $132.34 |
52-Week Low | $26.19 | $89.53 |
Typical Hold Time | 0 Days | 74 Days |
Enterprise Value | $4.31B | $19.81B |
Dividend Yield | — | 3.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SJM trades at $121.84, up 1.52% today, with a bullish technical signal and strong recent earnings beats. The company reported Q2 2026 EPS of $3.24, beating expectations, and raised FY27 guidance. However, 2025 fundamentals show a net loss of $1.23B and elevated P/E of 56.7, while analyst consensus is a Buy with a $138.23 price target.
Outlook is mixed; robust growth in segments like Uncrustables and raised guidance support upside, but high valuation, volatile profitability, and debt levels pose risks. The stock offers a dividend yield but faces competitive and margin pressures in the consumer staples sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
